Hello, it looks like you are visiting from United States / Estados Unidos Language US Go to United States (English) / Estados Unidos (español) site

An estimated 5 billion people, or half the global population, could be affected by myopia by 2050.

Myopia is a global concern.

Annual myopia progression rate is most rapid under 10 years of age. Significantly greater rates of progression can be seen especially in children with high myopia.

If left untreated, myopia can lead to lasting vision problems. But together we can tackle myopia in children

An innovative spectacle lens.

This spectacle lens based on revolutinary Defocus Incorporated Multiple Segments (D.I.M.S.) Technology was developed in cooperation with The Hong Kong Polytechnic University in 2014. MiYOSMART is easy to fit, just like regular single vision lens. There are no limitations for the frame choice.

 

In 2018, the MiYOSMART lens won the Gold Prize, Grand Award & Special Gold Award International Exhibition of Inventions of Geneva, Switzerland. In 2020, it won the Silmo d’Or Award in the Vision category at the Silmo Paris Optical Fair.

A revolutionary technology.

With the exclusive non-invasive D.I.M.S. Technology, the lens corrects the visual defect on its entire surface and has a ring shaped treatment area to slow down myopia progression. The alternation of the focus area and defocus area provides clear vision and manages myopia simultaneously.

Scientific Evidence of MiYOSMART

2-year Randomized Clinical Trial

Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomized clinical trial (BJO)

Read the full study

3-year Follow-up Study

Myopia control effect of defocus incorporated multiple segments (DIMS) spectacle lens in Chinese children: results of a 3-year follow-up study (BJO)

Read the full study

6-year Follow-up Study

Long-term myopia control effect and safety in children wearing DIMS spectacle lenses for 6 years

Read the full study

Overview of MiYOSMART Evidence

Discover the full overview of all MiYOSMART evidence to date. More than 25 publications from across the globe conducted on the MiYOSMART D.I.M.S. Technology over the years.

Read the full study

MiYOSMART SUN - Protect How They See the World

With MiYOSMART Sun, slowing of myopia progression and protection from intense sunlight come together.2-6†

MiYOSMART Sun spectacle lenses adopted D.I.M.S. Technology for effective myopia management and correction of myopic refractive error, while protecting from intense sunlight and increasing eye comfort.2-6

Just like MiYOSMART clear spectacle lenses, MiYOSMART sun spectacle lenses offer 100% protection from UV-A and UV-B,7* reducing the risk of long-term damage to the eye.

*As per EN ISO 8980-3:2013 and ANSI Z80.3-2015 Standards.

††Assuming photochromic spectacle lenses are used at all times or in addition to MiYOSMART clear spectacles lenses, or polarized spectacle lenses are used in addition to MiYOSMART clear spectacle lenses. Patients should always consult their Eye Care Professionals for treatment decisions and instructions for use.

Find out more

Published scientific studies in the British Journal of Ophthalmology:

Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomized clinical trial. (Published 11 Dec. 2019)

read article

Myopia control effect of Defocus Incorporated Multiple Segments (DIMS) spectacle lens in Chinese children: results of a 3-year follow-up study. (Published Online First: 17 March 2021)

read article
Image of children wearing classes within a classroom

Designed to fit a child’s active life.

MiYOSMART comes with an easy-to-wipe special anti-reflective, durable coating. With its Eye Shield, young patients get the added assurance of an impact resistant material and UV protection.

Image of children wearing classes within a classroom

*PRODUCT DISCLAIMER – MiYOSMART has not been approved for myopia management in all countries, including the U.S., and is not currently available for sale in all countries, including the U.S.

1 Brien Holden Vision Institute; 2 Shanghai Eye Disease Prevention and Treatment Center https://guidelines.brienholdenvision.org, accessed 16.08.1018.

2 Lam CSY, Tang WC, Lee RPK, Chun RKM, To CH. A randomized clinical trial for myopia control – use of myopic defocus spectacle lens. 8th International Congress of Behavioral Optometry (ICBO), 26- 29 of April 2018. Sydney, Australia. 8Sankaridurg P1, Tilia D1, Morton M1, Weng R1, Jong M1, Zhu F2. Guidelines for Myopia Management.